FTO and acute myeloid leukemia: The FTO inhibitor FB23–2 increases global m6A levels, suppresses leukemic stem-cell self-renewal, and enhances the expression of pro-immune cytokines in acute myeloid leukemia models; when combined with ibrutinib or checkpoint blockade, FB23–2 augments cytotoxic T-cell activity and improves survival (15).